1. Value the backlog, not the quarter — buy contracted future revenue at a discount
The repeatable method
- For a project-based industrial (engineering, construction, defense), pull the backlog and divide by annual revenue — over ~2x means years of revenue is already signed and hard to cancel.
- Check the trajectory: book-to-bill above 1.0 (here 1.4x TTM, 2.0x in the quarter) means new awards are out-pacing recognition — the backlog is growing, not draining.
- Read the backlog composition — is it pointed at end-markets with secular spending (AI data centers, semis, water, nuclear), or at a fading cycle? Composition matters more than size.
- Compare the multiple to the contracted visibility: a 2x+ growing backlog at <17× earnings means the market is paying nothing for the order book.
Here: J — $26.3B backlog (+20.6%) ≈ 2+ years of revenue, book-to-bill 2.0x, led by data centers / semis / life-sciences / water, yet trading ~16.7× fwd EPS vs peers (PWR, ACM, TTEK) at 20–25×.
Watch for
- Book-to-bill slipping below 1.0, or backlog growth decelerating — the first sign the visibility is eroding.
2. De-risk a "scary" backlog with the contract-mix footnote
The repeatable method
- A large backlog of complex multi-year projects raises cost-overrun fear — so check the 10-K for the cost-reimbursable vs fixed-price-at-risk split.
- Cost-reimbursable / cost-plus work passes overruns to the client; fixed-price-at-risk is where write-downs happen. A high cost-reimbursable share caps the downside of backlog conversion.
- Confirm with the actual flagship-project record — one over-budget showcase project (vs a portfolio-wide pattern) is a reputational dent, not a thesis-breaker.
Here: 68% of J's continuing-ops revenue is cost-reimbursable and fixed-price-at-risk was 0% of FY25 revenue — so even the Hinkley Point C overrun (3× cost/schedule) is contained.
Watch for
- Any drift of new awards toward fixed-price terms; a second flagship project running over budget.
3. Re-recommend the "dud" — re-underwrite a flat name after the business has changed
The repeatable method
- When a past pick has gone nowhere, don't just average down on the old thesis — ask whether the business itself changed (a spin-off, an acquisition, a new segment mix).
- If the company is structurally cleaner than when you wrote it up, the flat price is now attached to a better business — a wider margin of safety, not a failed call.
- Be honest about the original mistake (here: failing to trim into the post-breakout strength) so the discipline carries into the re-entry.
Here: J sits at ~its March-2024 price, but the Sept-2024 Amentum spin-off + full PA Consulting ownership made it a focused, higher-margin company — so "the same price" buys a different, better business.
Watch for
- Spin-offs / divestitures that leave a cleaner remaining business; the temptation to re-buy on the old story rather than the new one.
4. Re-map the crisis — find the names where the headline fear is actually demand
The repeatable method
- When a sector is sold indiscriminately on a macro fear, ask whether that same fear raises spending in a particular company's end-markets.
- An energy-security shock accelerates nuclear / LNG / water / coastal-protection programs; an AI-capex boom needs physical data-center and semiconductor construction — both flow to the engineer that builds them.
- Buy the builder that's being sold with the complex while its order pipeline is being filled by the very crisis driving the selling.
Here: J sold off with industrials on Hormuz/tariff fear, but the Hormuz shock fast-tracks the nuclear/water programs it engineers (Sizewell C, Gulf Coast surge barrier) and the AI buildout fills its data-center/semis pipeline ($400–500B 2026 capex).
Watch for
- Sectors dumped on a macro headline whose underlying capex driver is actually accelerating; inquiry/engagement commentary on the earnings call as the leading tell.
5. The open-market insider-buy cluster — management voting with its own cash
The repeatable method
- Separate open-market purchases (cash out of pocket) from option exercises/grants — only purchases are a signal.
- A cluster of buys across multiple roles (CFO + board member + director) in a short window is stronger than a single buyer.
- Cross-check it against the bear case: if insiders are buying while the market frets about execution, they're not acting worried.
Here: three J insiders — the CFO, a board member and a director — bought in the open market in the prior six months, "not acting like a management team worried about execution."
Watch for
- Form 4 open-market buy clusters; the contrast between insider buying and a bearish sell-side narrative.
6. The capital-return floor — shrinking share count + FCF-yield math
The repeatable method
- Confirm a stated payout policy (here: ≥60% of FCF) and that the share count is actually falling (J −3.1% YoY) and the dividend rising (+12.5%).
- Compute the FCF yield from the FCF-margin guide (J: 7–8.5% margin → ~$770M–$1B FCF on a ~$15B cap = ~5–6.5% yield) and pair it with the earnings growth rate.
- A mid-single-digit FCF yield with double-digit earnings growth is the combination that supports a re-rating without needing heroic assumptions.
Here: J's ~5–6.5% FCF yield + 15%+ EPS growth + a shrinking float underpins the 21–22× FY27 EPS $8–8.50 → $168–187 target.
Watch for
- Buyback pace slowing or leverage rising — a sign the capital-return floor is weakening.